All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
An oral session on lymphoma took place at the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting on 19 March 2018. Abstract OS1-7 was presented by Enrico Derenzini from the European Institute of Oncology, Milan, Italy, on the effect of immune checkpoint activation following allogeneic stem cell transplantation (allo-SCT) in lymphoma patients.
Immune checkpoint inhibitors, like the anti-programmed death 1 (PD-1) and the anti-programmed death ligand 1 (PD-L1) antibodies have attracted a lot of clinical attention due to their high therapeutic potential in lymphoma, as immune cell-tumor interaction suppressors. Moreover, it has been reported that PD-1/PD-L1 and the lymphocyte activation gene-3 (LAG3)—a known PD-1/PD-L1 interactor protein—cooperate in promoting immune escape in cancer. In this retrospective study, the authors investigated whether the expression levels of PD-1, PD-L1 or LAG3 can predict clinical outcomes in pre-transplant tumors of lymphoma patients that received allo-SCT. Primary endpoints included progression-free survival (PFS), overall survival (OS)
The results of this retrospective pilot study further validate the therapeutic potential of anti-PD-1/PD-L1 immune checkpoint inhibitors and the hypothesis that immune checkpoint activation can lead to poorer clinical outcomes, since significantly inferior 5-year PFS was observed in patients after allo-SCT with higher PD-1, PD-L1 and/or LAG3 expression. Moreover, combined PD-1, PD-L1 and LAG3 expression was higher in lymphoma patients progressing or relapsing after allo-SCT. These preliminary results are suggestive of the biomarker potential of PD-1, PD-L1 and/or LAG3 expression for predicting clinical outcomes in lymphoma patients undergoing allo-SCT.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox